The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China

Frontiers in Oncology

Oncology

Ke Zhuang¹  Yajun Yan²  Zhiyong Ma³  Shan Wang³  Xiaoping Chen³  Liping Deng³  Yong Xiong³  Pingzheng Mo⁴  Yongxi Zhang⁴  Yu Xiong⁵  Di Deng⁵ 

[1] ABSL-III Laboratory at the Center for Animal Experiment, Wuhan University, Wuhan, Hubei, China;Centre of AIDS Prevention and Cure, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China;Centre of AIDS Prevention and Cure, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China;Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China;Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China;

关键词: HIV;    cancer;    camrelizumab;    immunotherapy;    PD-1;   

DOI  :  10.3389/fonc.2023.1248790

 received in 2023-06-27, accepted in 2023-08-21,  发布年份 2023

来源: Frontiers

【 摘 要 】

Purpose-Immunotherapy has revolutionized cancer therapy, becoming the standard of care for various malignancy treatments. Human immunodeficiency virus (HIV) patients, however, are an underserved group with limited access to clinical trials and cancer therapy. This study was to evaluate the safety and efficacy of programmed cell death 1 (PD - 1) inhibitors in patients with advanced cancer and HIV/acquired immunodeficiency syndrome (AIDS). Methods and Materials-We performed a prospective, open-label, nonrandomized, phase 1 single center study. Patients with advanced cancer and HIV/AIDS received the treatment of PD - 1 inhibitors (camrelizumab, 200 mg, administered intravenously every 3 weeks), along with combination antiretroviral therapy (cART) for HIV. Results-Sixteen participants (12 men and 4 women; median age, 46.5 (29 - 78) years) were enrolled; 1 had non - Hodgkin lymphoma (NHL), and 15 had non - AIDS - defining cancers. Safety was observed over 130 cycles of treatment with camrelizumab. Most treatment-emergent adverse events at least possibly attributed to camrelizumab were grade 1 or 2, including reactive cutaneous capillary endothelial proliferation (RCCEP) (9 participants), hearing loss (1 participant), hypophysitis (1 participant). 3 participants experienced hemorrhage due to poor performance status. HIV was controlled in all participants. Best tumor responses included 3 complete response, 5 partial response, 2 stable disease, and 6 progressive disease. The 2 years progression-free survival (PFS) was 67.0% (95% CI: -0.05, 0.00) and overall survival (OS) was 55.3% (95% CI: -0.05, 0.01) for the 16 patients who had received camrelizumab. Conclusions-This study demonstrates that camrelizumab treatment in patients with advanced cancers and HIV/AIDS was feasible and the clinical outcomes were acceptable.

【 授权许可】

Unknown   
Copyright © 2023 Xiong, Mo, Yan, Wang, Zhuang, Ma, Chen, Deng, Xiong, Deng and Zhang